Are you Dr. Lubiniecki?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 105 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
333 Cottman Ave
Philadelphia, PA 19111Phone+1 215-728-2500Fax+1 215-728-3639
Summary
- Dr. Gregory Lubiniecki, MD is an oncologist in Philadelphia, Pennsylvania. He is currently licensed to practice medicine in Pennsylvania, New Jersey, and Minnesota. He is affiliated with Fox Chase Cancer Center.
Education & Training
University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2001 - 2004
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 1998 - 2001
Johns Hopkins University School of MedicineClass of 1998
Certifications & Licensure
PA State Medical License 2001 - 2024
NJ State Medical License 2004 - 2009
MN State Medical License 1999 - 2001
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Publications & Presentations
PubMed
- 6723 citationsPembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung CancerMartin Reck, Delvys Rodriguez-Abreu, Andrew G. Robinson, Rina Hui, Tibor Csőszi
The New England Journal of Medicine. 2016-10-08 - 2061 citationsPembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, op...Tony Mok, Yi-Long Wu, Iveta Kudaba, Dariusz M. Kowalski, Byoung Chul Cho
Lancet. 2019-05-04 - 4500 citationsPembrolizumab for the treatment of non-small cell lung cancerEdward B. Garon, Naiyer A. Rizvi, Rina Hui, Natasha B. Leighl, Ani Sarkis Balmanoukian
The New England Journal of Medicine. 2015-05-20
Press Mentions
FDA Approves Merck’s KEYTRUDA® (Pembrolizumab) plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients with Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma (MPM)September 18th, 2024- KEYTRUDA® (Pembrolizumab) plus LENVIMA® (Lenvatinib) in Combination with Transarterial Chemoembolization Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients with Unresectable, Non-Metastatic Hepatocellular CarcinomaSeptember 14th, 2024
- Merck and Eisai Provide Update on Phase 3 Trials of KEYTRUDA® (Pembrolizumab) plus LENVIMA® (Lenvatinib) in Certain Patients with Advanced Melanoma (LEAP-003) and Metastatic Colorectal Cancer (LEAP-017)April 7th, 2023
- Join now to see all
Professional Memberships
- Member
